亚太地区分子肿瘤诊断市场（按癌症类型、最终用户和国家划分）分析与预测（2024 年至 2033 年）

预计2024年亚太地区分子肿瘤诊断市场规模将达5.136亿美元。

预计到2033年，该市场规模将达到15.42亿美元，复合年增长率为12.99%。数位PCR、液态切片和次世代定序（NGS）是推动亚太地区分子癌症诊断市场爆炸性成长的关键技术驱动力。中国、印度和日本等国家的癌症发生率上升，推动了人们对更早发现、更精准治疗方法方案以及最终改善患者预后的需求。

然而，一些地区性障碍阻碍了该技术的广泛应用。先进分子诊断的高成本仍然是一大障碍，尤其是在东南亚等医疗资源匮乏的市场。此外，该地区许多地区缺乏能够运作先进诊断系统并解读大量基因组数据的合格专业人员。

儘管面临这些障碍，亚太市场仍在持续成长。创新正在加速，生物技术、製药、诊断试剂製造商和学术机构之间的合作正在将分子工具整合到常规肿瘤学工作流程中。为了充分实现精准癌症诊断的前景，相关人员需要规范报销流程，透过本地生产和规模化生产降低检测成本，并资助培训项目，以提高各医疗体系临床医生的基因组学素养。

市场介绍

随着中国、印度、日本和东南亚的医疗体系更加重视精准医疗，亚太地区的癌症分子诊断市场预计将快速成长。分子检测，尤其是次世代定序(NGS)、数位 PCR 和液态切片，的使用正在增加，因为它们可以比传统技术更准确、更早地识别癌症相关的基因变异。这些尖端仪器的需求是由于大肠癌、肺癌和乳癌发生率的上升，以及患者和医生意识的提高。国家基因组计划、伴随诊断建议以及公共和私人对实验室基础设施的投资也推动了临床应用。高昂的测试价格、脱节的监管程序以及合格的生物资讯学家和分子技术人员的短缺，尤其是在低收入地区，仍然是主要障碍。

为了克服这些障碍，产业相关人员正在建立策略联盟，提高本地生产能力，并实施培训计画以发展技术专长。同时，自动化、高通量平台的引进也加快了流程并缩短了交货时间。未来，人工智慧驱动的生物资讯学、扩大的保险覆盖范围以及更强大的数据安全框架的结合，对于推动该行业的长期扩张至关重要。透过在各种医疗环境中提供更个人化和高效的癌症治疗，预计到2030年，亚太地区分子肿瘤诊断市场将在全球精准肿瘤学市场中占据重要份额。

市场区隔

细分一：按癌症类型

• 固体癌
• 骨髓恶性肿瘤

细分 2：按最终用户

• 医院和诊断中心
• 参考实验室
• 製药和生物技术公司
• 学术和研究机构

第 3 部分：按地区

• 亚太地区－日本、中国、印度、韩国、澳洲、世界其他地区

亚太地区分子肿瘤诊断市场趋势、驱动因素与挑战：

市场趋势

• 技术进步：次世代定序仪(NGS)、数位 PCR 和液态切片(ctDNA/ctC) 无创即时癌症监测的快速应用
• 整合与伙伴关係：活性化将重塑竞争格局，大型实验室和诊断机构将收购或与领先平台合作。
• 伴随诊断整合：受日本和澳洲等主要市场监管指南不断演变的推动，采用伴随诊断检测来匹配患者和标靶治疗正在日益增多。
• 自动化和高通量平台：为了提高效率和试样处理通量，临床和研究实验室都在采用自动化系统。

市场驱动因素

• 癌症发生率上升：中国、印度、日本和东南亚的乳癌、肺癌和大肠癌发生率急剧上升，刺激了对精准诊断的需求。
• 推动精准医疗：个人化肿瘤学正在成为策略转变，付款人和提供者都投资于基因型指导的治疗途径。
• 政府和公私合作倡议：进行基础设施扩建的国家计画和伙伴关係，例如基因组学使命和伴随诊断指南。
• 医疗基础设施投资：资金流入实验室升级、生物技术研发和专门的癌症中心将增强当地的能力。

市场挑战

• 检测成本高：先进的分子检测仍然价格昂贵，限制了其在低收入亚太市场的采用。
• 监管复杂性：各国核准途径分散且不断变化，导致产品上市延迟。
• 缺乏技术人员：训练有素的分子技术人员和生物资讯学家的短缺阻碍了更广泛的临床部署。
• 资料安全和隐私：处理敏感的基因组和病患资料会引发合规性和网路安全问题。

目录

执行摘要

第一章 分子肿瘤诊断市场：产业展望

• 全球癌症发生率和盛行率（按癌症类型划分）
  • 亚太地区
• 趋势：现况与未来影响评估
  • 加强参与企业间的伙伴关係
  • 增加分子肿瘤诊断生态系统中的创新产品发布和监管核准
• 监管状况
  • 亚太地区的法律要求与框架
• COVID-19 对分子肿瘤诊断市场的影响
• 基于液态生物检体的分子癌症诊断
• 实验室测试（LDT）和体外诊断（IVD）
• 伴随诊断在分子肿瘤诊断市场中的作用
• 市场动态
  • 市场驱动因素
  • 市场挑战
  • 市场机会

第二章 分子肿瘤诊断市场（按地区）

• 区域摘要
• 驱动因素和约束因素
• 亚太地区
  • 区域概况
  • 市场成长动力
  • 成长抑制因素
  • 按癌症类型
  • 按最终用户
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 其他的
• 其他地区

3. 分子肿瘤诊断市场竞争基准化分析与公司概况

• 公司简介
  • Sysmex Corporation

第四章调查方法

This report can be delivered in 2 working days.

Introduction to Asia-Pacific Molecular Oncology Diagnostics Market

The Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1,542.0 million by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan.

However, a number of regional obstacles prevent wider implementation. In markets with smaller healthcare resources, especially in Southeast Asia, the high cost of advanced molecular diagnostics continues to be a significant barrier. Furthermore, in many areas of the region, there is a lack of qualified experts who can run sophisticated diagnostic systems and decipher massive amounts of genomic data.

The APAC market is still growing in spite of these obstacles. Innovation is being accelerated and molecular tools are being incorporated into routine oncology workflows through cooperative efforts between biotech businesses, pharmaceutical companies, diagnostic manufacturers, and academic institutions. Stakeholders must standardise reimbursement practices, reduce test costs through local and scaled production, and fund training initiatives to increase clinician genomic literacy across various healthcare systems if they are to fully realise the promise of precision cancer diagnostics.

Market Introduction

The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major obstacles.

Industry participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030.

Market Segmentation:

Segmentation 1: by Cancer Type

• Solid Tumors
• Hematologic Malignancies

Segmentation 2: by End User

• Hospitals and Diagnostic Centers
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Segmentation 3: by Region

• Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific

APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges:

Market Trends

• Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring.
• Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms.
• Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia.
• Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput.

Market Drivers

• Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics.
• Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways.
• Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines.
• Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity.

Market Challenges

• High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets.
• Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches.
• Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout.
• Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns.

Table of Contents

Executive Summary

Scope and Definition

1 Molecular Oncology Diagnostics Market: Industry Outlook

• 1.1 Global Incidence and Prevalence of Cancer (by Cancer Type)
  • 1.1.1 Asia-Pacific
• 1.2 Trends: Current and Future Impact Assessment
  • 1.2.1 Increasing Partnerships among Players
  • 1.2.2 Increasing Launch of Innovative Products and Regulatory Approvals in Molecular Oncology Diagnostics Ecosystem
• 1.3 Regulatory Landscape
  • 1.3.1 Legal Requirements and Framework in Asia-Pacific
    • 1.3.1.1 China
    • 1.3.1.2 Japan
• 1.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market
• 1.5 Liquid Biopsy-Based Cancer Molecular Diagnostics
• 1.6 Laboratory-Developed Test (LDT) vs. In-Vitro Diagnostics (IVD)
• 1.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market
• 1.8 Market Dynamics
  • 1.8.1 Market Drivers
    • 1.8.1.1 Rising Incidence of Cancer Cases
    • 1.8.1.2 Rising Technological Advancements in Molecular Diagnostics
    • 1.8.1.3 Growth in Biomarker Identification and Transformations in Molecular Techniques
    • 1.8.1.4 Growing Demand for Personalized Medicine
  • 1.8.2 Market Challenges
    • 1.8.2.1 Lack of Qualified Professionals
    • 1.8.2.2 High Cost of Molecular Diagnostic Kits and Assays Hindering the Adoption Rate
  • 1.8.3 Market Opportunities
    • 1.8.3.1 Focus on Reimbursement and Medical Coverage for Molecular Oncology Diagnostics
    • 1.8.3.2 Focus on Next-Generation Ultrasensitive Molecular Diagnostics
    • 1.8.3.3 Increasing Growth Opportunities for Molecular Diagnostics Companies in Emerging Economies

2 Molecular Oncology Diagnostics Market: by Region

• 2.1 Regional Summary
• 2.2 Drivers and Restraints
• 2.3 Asia-Pacific
  • 2.3.1 Regional Overview
  • 2.3.2 Driving Factors for Market Growth
  • 2.3.3 Factors Challenging the Market
  • 2.3.4 By Cancer Type
  • 2.3.5 By End User
  • 2.3.6 China
    • 2.3.6.1 By Cancer Type
    • 2.3.6.2 By End User
  • 2.3.7 India
    • 2.3.7.1 By Cancer Type
    • 2.3.7.2 By End User
  • 2.3.8 Japan
    • 2.3.8.1 By Cancer Type By End User
  • 2.3.9 South Korea
    • 2.3.9.1 By Cancer Type
    • 2.3.9.2 By End User
  • 2.3.10 Australia
    • 2.3.10.1 By Cancer Type
    • 2.3.10.2 By End User
  • 2.3.11 Rest-of-Asia-Pacific
    • 2.3.11.1 By Cancer Type
    • 2.3.11.2 By End User
• 2.4 Rest-of-the-World
  • 2.4.1 Regional Overview
  • 2.4.2 Driving Factors for Market Growth
  • 2.4.3 Factors Challenging the Market
  • 2.4.4 By Cancer Type
  • 2.4.5 By End User

3 Molecular Oncology Diagnostics Market - Competitive Benchmarking & Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Sysmex Corporation
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Target Customers/End User
    • 3.1.1.5 Key Personnel
    • 3.1.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1 Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2024, 2028, and 2033
• Figure 2 Molecular Oncology Diagnostics Market (by Region), $Million, 2023, 2027, and 2033
• Figure 3 Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023, 2027, and 2033
• Figure 4 Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023, 2027, and 2033
• Figure 5 Role of Diagnostics in Healthcare
• Figure 6 Cancer Prevalence and Incidence (by Cancer Type), in Million, Asia-Pacific, 2022
• Figure 7 Workflow for Medical Device Regulations
• Figure 8 Technological Advances in Liquid Biopsy Analysis
• Figure 9 List of Some Liquid Biopsy-Based Available Tests Approved by FDA/CE-IVD
• Figure 10 Impact Analysis of Market Navigating Factors, 2022-2033
• Figure 11 Global Distribution of Cases and Deaths (by Cancer Type), 2022
• Figure 12 Global Incidence for Cancer Types, 2018-2022
• Figure 13 China Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 14 India Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 15 Japan Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 16 South Korea Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 17 Australia Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 18 Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2023-2033
• Figure 19 Data Triangulation
• Figure 20 Top-Down and Bottom-Up Approach
• Figure 21 Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Key Trends, Impact Analysis
• Table 3: Molecular Oncology Diagnostics Market, Partnerships and Collaborations
• Table 4: Molecular Oncology Diagnostics Market, Product Launches and Regulatory Approvals
• Table 5: Prominent FDA-Approved Companion Diagnostics
• Table 6: Molecular Oncology Diagnostics Market, New Offerings
• Table 7: Biomarkers for Different Cancer Types
• Table 8: Significance of Different Biomarkers in Clinical Outcomes of Various Cancer
• Table 9: Cost of Liquid Biopsy-Based NGS Kits
• Table 10: Molecular Oncology Diagnostics Market, Reimbursement and Medical Coverage
• Table 11: Molecular Oncology Diagnostics Market (by Region), $Million, 2023-2033
• Table 12: Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 13: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 14: Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 15: Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 16: China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 17: China Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 18: China Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 19: China Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 20: India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 21: India Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 22: India Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 23: India Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 24: Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 25: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 26: Japan Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 27: Japan Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 28: South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 29: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 30: South Korea Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 31: South Korea Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 32: Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 33: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 34: Australia Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 35: Australia Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
• Table 36: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
• Table 37: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
• Table 38: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
• Table 39: Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033